ArticleCancer management and research2022

Forthcoming Phase II Study of Durvalumab (MEDI4736) Plus Chemotherapy for Small Cell Lung Cancer with Brain Metastases.

Yoshimasa Shiraishi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.